![](https://cdn.sanity.io/images/0vv8moc6/neurolive/33c16133acb87b5f797767db9bcc3b1cf06b80f5-300x300.png?fit=crop&auto=format)
FDA Grants Regenerative Medicine Advanced Therapy Designation to Kyverna's KYV-101 for Refractory Stiff-Person Syndrome
According to a recent announcement, the FDA has granted regenerative Medicine Advanced Therapy (RMAT) designation to Kyverna Therapeutics’s KYV-101, an investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of …